About the Authors

David B. Shultz

Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Jonathan Pai

Affiliation School of Medicine, University of California San Francisco, San Francisco, United States of America

Wayland Chiu

Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

Kendall Ng

Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

Madeline G. Hellendag

Affiliation Kaiser Permanente Medical Center, San Francisco, United States of America

Gregory Heestand

Affiliation Moores Cancer Center, University of California San Diego, La Jolla, CA, United States of America

Daniel T. Chang

Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

Dongsheng Tu

Affiliation NCIC Clinical Trials Group, Queen's University, Kingston, Canada

Malcolm J. Moore

Affiliation British Columbia Cancer Agency, Vancouver, British Columbia, CA, United States of America

Wendy R. Parulekar

Affiliation NCIC Clinical Trials Group, Queen's University, Kingston, Canada

Albert C. Koong

akoong@stanford.edu

Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

Competing Interests

The authors have read the journal's policy and the authors of this manuscript have the following competing interests: GH has served as a consultant for Bayer, Merrimack, and Genomic Health. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: DS WP AK. Performed the experiments: JP WC KN MH GH DT. Analyzed the data: DS JP WC KN MH DT WP AK. Contributed reagents/materials/analysis tools: MH GH MM WP AK. Wrote the paper: DS DC AK.